Search

What is the goal of your paper? What questions did you seek to answer? Digital health is an emerging discipline that utilizes hardware and software tools to improve healthcare delivery efficiency and accessibility. Technologies that fall under the digital health umbrella include mobile phone applications, telemedicine, and social media networks. The goal of this review is to highlight two mobile phone applications that were developed for premature ejaculation and Peyronie’s disease. Summarize the latest research on your topic. Through the course of our review, we aim to highlight how these applications were conceived, the manner in which users interface with these tools and future directions for these software solutions. We identified that patients and practitioners alike are creating digital health solutions based upon personal and clinical experiences. What answers did you find? What are the major takeaways/conclusions of your examination? What’s the impact on future research? The major takeaway of our examination is that digital health is an emerging area of innovation and investigation. Existing solutions however need further real-world evaluation to assess their clinical validity.

Approximately half a million men each year facing infertility in the USA are not properly evaluated by a dedicated male infertility specialist. Prior research has examined barriers to male infertility care from epidemiologic, geographic, financial, socioeconomic, and health policy perspectives. This article aims to describe barriers to male infertility care that have traditionally received less consideration and to suggest innovative solutions for enhancing access to care. We explore how the portrayal of male infertility in television shows, movies, and news media shapes the public perception of male infertility. We then define how social networking websites influence awareness and engagement with the concept of male infertility. In addition, potential avenues for collaboration with other medical providers to increase the frequency of male infertility workups are discussed. Finally, we touch on how funding for basic science and clinical research shapes the spectrum of available treatment options and briefly review state-of-the-art research in male infertility. Access to dedicated male infertility care represents an unmet public health need in the USA. Using an atypical lens, the authors’ goal is to provide a brief review of issues surrounding access to male infertility care and to highlight new avenues to enhance access.

BACKGROUND: The constellation of persistent sexual, neurological, and physical adverse effects in patients who discontinue 5α-reductase inhibitors (5ARIs) has garnered recent concern. The objective of this study was to evaluate potential penile vascular changes and persistent adverse effects of 5ARIs in men treated for androgenic alopecia (AGA). METHODS: This was a prospective case-control study with 25 subjects with a history of 5ARI use for AGA and 28 controls. Patient self-reported questionnaires including the International Index of Erectile Function (IIEF), International Prostate Symptom Score (IPSS), Patient Health Questionnaire-9 (PHQ-9), the Epworth Sleepiness Scale (ESS) and the Androgen Deficiency in the Aging Male (ADAM) were used. Penile duplex Doppler ultrasound (PDDU) results were evaluated in men with a history of 5ARI use. RESULTS: A significant difference in total IIEF score between the 5ARI (median: 35; IQR: 29–43) and control group (median: 29; IQR: 27–32) (P=0.035) was observed. Seventeen 5ARI subjects (68%) had a vascular abnormality on PDDU. The median (IQR) for total IPSS score for the 5ARI group was 10 [5–16] compared to 3 [2–8] for the controls (P

Male hypogonadism is an increasingly prevalent clinical condition that affects patients’ quality of life and overall health. Obesity and metabolic syndrome can both cause and result from hypogonadism. Although testosterone remains the gold standard for hypogonadism management, its benefits are not always conserved across different populations, especially with regards to changes in body composition. Partially in response to this, growth hormone secretagogues (GHS) have emerged as a potential novel adjunctive therapy for some of the symptoms of hypogonadism, although current data on their clinical efficacy largely remain lacking. The present review examines the existing literature on the use of GHS and explores their potential complementary role in the management of hypogonadal and eugonadal males with metabolic syndrome or subclinical hypogonadism (SH). The GHS that will be discussed include sermorelin, growth hormone-releasing peptides (GHRP)-2, GHRP-6, ibutamoren, and ipamorelin. All are potent GH and IGF-1 stimulators that can significantly improve body composition while ameliorating specific hypogonadal symptoms including fat gain and muscular atrophy. However, a paucity of data examining the clinical effects of these compounds currently limits our understanding of GHS’ role in the treatment of men with hypogonadism, but does open opportunities for future investigation.

Introduction Erectile dysfunction (ED) is the inability to attain or sustain an erection for sexual intercourse. Affected men endorse difficulties with intimacy and feelings of guilt and shame. Although medical treatments are available, patients are reluctant to discuss ED with physicians and often use dietary supplements to attempt to treat their ED. As such, there is a need to better understand the effects of ingredients used in nutraceuticals for ED treatment. Objectives To summarize the literature on the efficacy and safety of the most common ingredients used in ED supplements. Methods 10 of the most common ingredients in ED supplements were reviewed using PubMed-indexed literature to assess their efficacy and safety in treating ED. Key findings were summarized to include historical use, active ingredients, prior animal studies, human studies, and toxicity. Results Nutraceuticals used in ED treatment include a variety of ingredients. Although L-arginine is a safe supplement with clinical data supporting improved erectile function, limited data exist on the efficacy of other ingredients in the treatment of ED. Conclusion Despite the growing use of supplements for treatment of sexual dysfunction, ED supplements remain poorly studied, with limited data demonstrating efficacy of individual ingredients. Further study is required to definitively determine the efficacy of nutraceuticals in ED treatment. Srivatsav A, Balasubramanian A, Pathak UI, et al. Efficacy and Safety of Common Ingredients in Aphrodisiacs Used for Erectile Dysfunction: A Review. J Sex Med 2020;8:431–442.

A large portion of US men suffer from sleep disorders. As many also engage in shift work, there is increased interest in determining how sleep disorders and shift work affect men's health. Links between sleep disorders and chronic illnesses including hypertension (HTN), diabetes mellitus (DM), cardiovascular disease (CVD), and obesity have been identified. Several relationships between sleep disorders and urological diseases have also been identified, including a link between disordered sleep and erectile dysfunction (ED), lower urinary tract symptoms (LUTS), and prostate cancer. As such, sleep disorders may have a more profound impact on the epidemiology and manifestation of these conditions and potentially others than has previously been acknowledged.

Introduction Selective androgen receptor modulators (SARMs) differentially bind to androgen receptors depending on each SARM’s chemical structure. As a result, SARMs result in anabolic cellular activity while avoiding many of the side effects of currently available anabolic steroids. SARMs have been studied in the treatment of breast cancer and cachexia and have also been used as performance-enhancing agents. Here, we evaluate and summarize the current literature on SARMs. Aim To present the background, mechanisms, current and potential clinical applications, as well as risks and benefits of SARMs. Methods A literature review was performed in MEDLINE using the terms selective androgen receptor modulator, hypogonadism, cachexia, breast cancer, benign prostatic hyperplasia, libido, and lean muscle mass. Both basic research and clinical studies were included. Main Outcome Measure To complete a review of peer-reviewed literature. Results Although there are currently no U.S. Food and Drug Agency-approved indications for SARMs, investigators are exploring the potential uses for these compounds. Basic research has focused on the pharmacokinetics and pharmacodynamics of these agents, demonstrating good availability with a paucity of drug interactions. Early clinical studies have demonstrated potential uses for SARMs in the treatment of cancer-related cachexia, benign prostatic hyperplasia (BPH), hypogonadism, and breast cancer, with positive results. Conclusion SARMs have numerous possible clinical applications, with promise for the safe use in the treatment of cachexia, BPH, hypogonadism, breast cancer, and prostate cancer. Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev 2019;7:84–94.